45E Stock Chart & Stats
€277.70
€4.60(1.98%)
At close: 4:00 PM EDT
€277.70
€4.60(1.98%)
Day’s Range― - ―
52-Week Range€158.00 - €375.70
Previous CloseN/A
Volume20.00
Average Volume (3M)35.00
Market Cap
€52.72B
Enterprise Value€38.04B
Total Cash (Recent Filing)€1.09B
Total Debt (Recent Filing)€238.49M
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Nov 11, 2026EPS Estimate
-0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.36
Shares Outstanding144,144,170
10 Day Avg. Volume65
30 Day Avg. Volume35
Financial Highlights & Ratios
PEG Ratio230.60
Price to Book (P/B)18.29
Price to Sales (P/S)13.58
P/FCF Ratio287.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€335.24Price Target Upside20.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
EPS Forecast (FY)-1.22
Revenue Forecast (FY)€2.59B
Bulls Say, Bears Say
Bulls Say
Strong Revenue And Volume GrowthRapid revenue growth, record test volumes, and a raised annual outlook indicate broadening clinical adoption across Natera’s businesses. Sustained volume expansion can improve laboratory utilization, strengthen payer and clinician relationships, and support durable operating leverage as newer products mature.
Regulatory And Guideline SupportMultiple regulatory approvals and leading guideline support strengthen Signatera’s clinical credibility and expand its addressable use cases. These milestones can improve physician adoption, facilitate reimbursement discussions, and create a more durable foundation for oncology testing growth over the coming quarters.
Improving Cash GenerationThe move to positive operating and free cash flow gives Natera greater flexibility to fund commercial expansion, clinical evidence, and product development internally. This reduces reliance on external capital and provides a stronger financial base while the company works toward consistent profitability.
Bears Say
Profitability Remains UnestablishedNatera has achieved substantial revenue scale and improved gross margins, but it still does not consistently convert that scale into operating earnings. Continued EBIT losses can constrain reinvestment capacity and leave results more sensitive to reimbursement, product mix, and spending decisions.
Reimbursement VariabilityRevenue true-ups introduce uncertainty into reported results and make quarterly performance less representative of underlying test utilization. Although management said the amounts are trending down, continued variability can complicate forecasting, cash conversion, and assessment of recurring reimbursement economics.
High Near-term Development InvestmentThe large early-cancer-detection investment may support a significant future opportunity, but it increases near-term R&D expense before commercial returns are available. This spending can delay profitability improvement and raises execution risk while the pivotal study and regulatory pathway progress.
45E FAQ
What was Natera’s price range in the past 12 months?
Natera lowest stock price was €158.00 and its highest was €375.70 in the past 12 months.
What is Natera’s market cap?
Natera’s market cap is €52.72B.
When is Natera’s upcoming earnings report date?
Natera’s upcoming earnings report date is Nov 11, 2026 which is in 35 days.
How were Natera’s earnings last quarter?
Natera released its earnings results on Aug 06, 2026. The company reported -€0.419 earnings per share for the quarter, beating the consensus estimate of -€0.44 by €0.021.
Is Natera overvalued?
According to Wall Street analysts Natera’s price is currently Undervalued.
Does Natera pay dividends?
Natera does not currently pay dividends.
What is Natera’s EPS estimate?
Natera’s EPS estimate is -0.23.
How many shares outstanding does Natera have?
Natera has 144,144,170 shares outstanding.
What happened to Natera’s price movement after its last earnings report?
Natera reported an EPS of -€0.419 in its last earnings report, beating expectations of -€0.44. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Natera?
Currently, no hedge funds are holding shares in DE:45E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Natera Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€335.24 (20.72% Upside)
€335.24 (20.72% Upside)
Blogger Sentiment
Bullish
DE:45E Sentiment 67%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
154.34%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
51.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Natera
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
45E Company Deck
45E Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational momentum and multiple high‑impact milestones (record volumes, robust revenue growth, major regulatory approvals, new guideline support, improved ASPs and margins, raised guidance, and a deep prospective clinical program). These positives are partially offset by near-term margin pressure from new product ramps, substantial investment in early cancer detection that depresses near-term profitability, reliance on future coverage actions for major ASP upside, and some one-time/variable SG&A items. Overall, the balance of evidence points to accelerating commercialization and durable long‑term opportunity despite expected short‑term investment and mix effects.View all DE:45E earnings summaries45E Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€335.24
▲(20.72% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month










